High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon. Results of a prospective, randomized, controlled trial

Journal of Clinical Gastroenterology

Volumn 34, Issue 2, 2002, Pages 177-182

  Fontana, Robert J ^a   Walsh, John ^a   Moyer, Cheryl A ^a   Lok, Anna S F ^a   Webster, Steven ^a   Klein, Steven ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antiviral therapy; Hepatitis C; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 0036147884     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200202000-00015     Document Type: Article

References (27)

1. National Institutes of Health consensus development conference panel statement: Management of hepatitis C
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C
3. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
4. A pilot study of combination therapy with ribavirin plus interferon alpha for alpha-interferon resistant chronic hepatitis C
5. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers
6. Interferon and ribavirin versus Interferon and amantidine in interferon non-responders with chronic hepatitis C
7. A randomized trial of ribavirin and interferon-a vs interferon-a alone in patients with chronic hepatitis C who were non-responders to a previous treatment
8. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
9. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials
10. Interferon and ribavirin vs Interferon alone in the retreatment of chronic hepatitis C previously nonresponsive to Interferon
11. A multicenter, randomized trial of daily high dose Interferon-alfa2b for the treatment of chronic hepatitis C: Pretreatment stratification by viral burden and genotype
12. Dose dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
13. Early HCV RNA values after interferon predict response
14. Hepatitis C virus infection: Quality of life and side effects of treatment
15. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C
16. Side effects of high-dose interferon therapy for chronic hepatitis C
17. Side effects of alpha interferon in chronic hepatitis C
18. Viral kinetics of the hepatitis C virus in patients treated with high dose daily combination therapy
19. Multicenter, randomized, controlled trial comparing high dose daily induction IFN plus ribavirin versus standard IFN plus ribavirin
20. Randomized trial of IFN induction and ribavirin versus standard IFN and ribavirin for chronic HCV in previously untreated patients
21. Is an "a la carte" combination interferon-alfa2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C
22. Interferon-alpha 2b and ribavirin in combination for chronic hepatitis patients not responding to Interferon alpha alone: An Italian, multicenter, randomized, controlled clinical study
23. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
24. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
25. Peginterferon alfa-2a in patients with chronic hepatitis C
26. PEGIFNa2b plus ribavirin compared with IFNa2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multi-international Phase III randomized, controlled trial
27. Pegylated (40kDa) Interferon alfa-2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study